Diseases characterized by injury or dysfunction involving multiple peripheral nerves and nerve roots. The process may primarily affect myelin or nerve axons. Two of the more common demyelinating forms are acute inflammatory polyradiculopathy (GUILLAIN-BARRE SYNDROME) and POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING. Polyradiculoneuritis refers to inflammation of multiple peripheral nerves and spinal nerve roots.
A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337)
Air that is reduced in volume by pressure.
An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
Disease or injury involving multiple SPINAL NERVE ROOTS. Polyradiculitis refers to inflammation of multiple spinal nerve roots.
Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.
Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.
Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
The propagation of the NERVE IMPULSE along the nerve away from the site of an excitation stimulus.

Antiganglioside antibodies in Guillain-Barre syndrome after a recent cytomegalovirus infection. (1/253)

OBJECTIVE: To study the association between anti-ganglioside antibody responses and Guillan-Barre syndrome (GBS) after a recent cytomegalovirus (CMV) infection. METHODS: Enzyme linked immunosorbant assay (ELISA) was undertaken on serum samples from 14 patients with GBS with recent cytomegalovirus (CMV) infection (CMV+GBS) and 12 without (CMV-GBS), 17 patients with other neurological diseases (OND), 11 patients with a recent CMV infection but without neurological involvement, 11 patients with recent Epstein-Barr virus (EBV) infection but without neurological involvement, and 20 normal control (NC) subjects. RESULTS: IgM antibodies were found at 1:100 serum dilution to gangliosides GM2 (six of 14 patients), GM1 (four of 14), GD1a (three of 14) and GD1b (two of 14) in the serum samples of the CMV+GBS patients, but not in those of any of the CMV-GBS patients. IgM antibodies were also found to gangliosides GM1, GD1a, and GD1b in one of 11 OND patients, to ganglioside GM1 in one of 11 non- neurological CMV patients, and to ganglioside GD1b in one of 20 NC subjects. Some patients with EBV infection had IgM antibodies to gangliosides GM1 (five of 11), GM2 (three of 11), and GD1a (two of 11). However, the antibodies to ganglioside GM2 had a low titre, none being positive at 1:200 dilution, whereas five of the CMV+GBS serum samples remained positive at this dilution. CONCLUSION: Antibodies to ganglioside GM2 are often associated with GBS after CMV infection, but their relevance is not known. It is unlikely that CMV infection and anti-ganglioside GM2 antibodies are solely responsible and an additional factor is required to elicit GBS.  (+info)

The risk of Guillain-Barre syndrome following infection with Campylobacter jejuni. (2/253)

To estimate the incidence of Guillain-Barre syndrome (GBS) following Campylobacter jejuni infection (CI) we studied three populations where outbreaks of CI had occurred involving an estimated 8000 cases. No case of GBS was detected in the 6 months following the outbreaks in the local populations. The point estimate for the risk of GBS following CI estimated in this study was 0 in 8000 (95% confidence interval 0-3).  (+info)

Ganglioside GM1 mimicry in Campylobacter strains from sporadic infections in the United States. (3/253)

To determine whether GM1-like epitopes in Campylobacter species are specific to O serotypes associated with Guillain-Barre syndrome (GBS) or whether they are frequent among random Campylobacter isolates causing enteritis, 275 random enteritis-associated isolates of Campylobacter jejuni were analyzed. To determine whether GM1-like epitopes in Campylobacter species are specific to O serotypes associated with Guillan-Barre syndrome (GBS) or whether they are frequent among random Campylobacter isolates causing enteritis, 275 enteritis-associated isolates, randomly collected in the United States, were analyzed using a cholera-toxin binding assay [corrected]. Overall, 26.2% of the isolates were positive for the GM1-like epitope. Of the 36 different O serotypes in the sample, 21 (58.3%) contained no strains positive for GM1, whereas in 6 serotypes (16.7%), >50% of isolates were positive for GM1. GBS-associated serotypes were more likely to contain strains positive for GM1 than were non-GBS-associated serotypes (37.8% vs. 15.1%, P=.0116). The results suggest that humans are frequently exposed to strains exhibiting GM1-like mimicry and, while certain serotypes may be more likely to possess GM1-like epitopes, the presence of GM1-like epitopes on Campylobacter strains does not itself trigger GBS.  (+info)

Antiganglioside antibody in patients with Guillain-Barre syndrome who show bulbar palsy as an initial symptom. (4/253)

OBJECTIVES: To identify valuable antiganglioside antibodies that support the diagnosis of Guillain-Barre syndrome (GBS) and its variants in patients showing bulbar palsy as an initial symptom. METHODS: Medical records of 602 patients with GBS or its variants were reviewed. Fifteen patients had bulbar palsy as an initial symptom. Serum antibodies against GM1, GM1b, GD1a, GalNAc-GD1a, GT1a, and GQ1b were examined in 13 of them. RESULTS: Serum antiganglioside antibodies were positive in 11 (85%) patients. IgG anti-GT1a (n=8; 62%) and anti-GM1b (n=7; 54%) antibodies were often present, whereas all the patients had low or no anti-GM1 antibody activity. High anti-GD1a and anti-GQ1b IgG antibody titres were also present in some patients, but most had higher IgG antibody titres to GM1b or GT1a. All five patients with high IgG antibody titre to GM1b or GT1a only had had antecedent diarrhoea. Some patients with pharyngeal-cervical-brachial weakness (PCB) had IgG antibody to GT1a which did not cross react with GQ1b. Other patients with PCB had antibody to GT1a which cross reacted with GQ1b or antibody to GM1b, but anti-GM1b and anti-GT1a antibodies were not associated with the presence of bulbar palsy. All the patients who had no IgG antiganglioside antibodies recovered completely. CONCLUSIONS: Measurement of serum IgG anti-GT1a and anti-GM1b antibodies gives helpful support for the diagnosis of GBS and its variants when there is early involvement of the oropharyngeal function independently of other neurological findings which appear as the illness progresses.  (+info)

Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. (5/253)

Although there are now widely accepted diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) there are few epidemiological data. A prevalence study was performed in the four Thames health regions, population 14 049 850. The prevalence date was 1 January 1995. Data were from a national consultant neurologist surveillance programme and the personal case series of two investigators. A diagnosis of CIDP was made according to definite, probable, possible, or suggestive diagnostic criteria. A wide difference in prevalence rates between the four health regions was noted, probably due to reporting bias. In the South East Thames Region, from which the data were most comprehensive the prevalence for definite and probable cases was 1.00/100 000; the highest total prevalence (if possible and suggestive cases were included) would have been 1.24/100 000. On the prevalence date 13% of patients required aid to walk and 54% were still receiving treatment.  (+info)

Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. (6/253)

We studied serum antibodies against gangliosides GQ1b and GM1 in 13 patients with Miller Fisher syndrome (MFS) and in 18 patients with Guillain-Barre syndrome (GBS) with cranial nerve involvement. Anti-GQ1b titers were elevated in all patients with MFS cases (immunoglobulin G [IgG] > IgA, IgM), and in 8 of the 18 with GBS. Lower frequencies of increased anti-GM1 titers were observed in MFS patients (3 of 13), as well as in GBS patients (5 of 18). During the course of MFS, anti-GQ1b titers of all Ig classes decreased within 3 weeks after onset. By contrast, anti-GM1 titers (mainly IgM) transiently increased during the course of MFS in five of six patients, suggesting a nonspecific secondary immune response. In patients with MFS following respiratory infections, IgG was the major anti-GQ1b Ig class (six of six patients) and IgG3 was the major subclass (five of six). In contrast, four of five patients with MFS following gastrointestinal infections showed predominance of anti-GQ1b IgA or IgM over IgG and predominance of the IgG2 subclass; anti-GQ1b IgG (IgG3) prevailed in one patient only. These distinct Ig patterns strongly suggest that different infections may trigger different mechanisms of anti-GQ1b production, such as via T-cell-dependent as opposed to T-cell-independent pathways. Thus, the origin of antibodies against GQ1b in MFS may be determined by the type of infectious agent that precipitates the disease.  (+info)

Short-term variability of blood pressure and heart rate in Guillain-Barre syndrome without respiratory failure. (7/253)

The effect of Guillain-Barre syndrome (GBS) on the short-term variability of blood pressure and heart rate was evaluated in six patients presenting with a moderate form of the syndrome, i.e. unable to stand up unaided and without respiratory failure, at the height of the disease and during recovery. The patients were compared with six age-matched healthy volunteers. During the acute phase of the syndrome, GBS patients exhibited a significant heart rate elevation (+26 beats/min compared with healthy subjects), but the acceleratory response to atropine, or to 60 degrees head-up tilt, was maintained. Resting plasma noradrenaline levels were high in acute GBS, but the secretory response to tilt was preserved. Desensitization to noradrenaline was observed in acute GBS with a reduced pressor action of this alpha-adrenoceptor agonist. Blood pressure levels were normal and head-up tilt did not induce orthostatic hypotension in this moderate form of GBS. Power spectral analysis demonstrated marked alterations in cardiovascular variability. The overall heart period variability was markedly reduced with the reduction predominantly in the high-frequency (respiratory) range (-73%). The low-frequency component of heart period variability was also reduced (-54%). This cardiovascular profile of moderate GBS at the height of the disease could result from a demyelination of the reflex loop controlling respiratory oscillations in heart rate and from a desensitization of the arterial tree to an elevated plasma noradrenaline. Sympathetic nervous activation may contribute to the high resting heart rate in acute GBS.  (+info)

Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross-reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barre syndrome. (8/253)

We examined the reactivity of a panel of anti-GM1 immunoglobulin M monoclonal antibodies (MAbs) cloned from multifocal motor neuropathy patients with lipopolysaccharides (LPSs) of Campylobacter jejuni strains, including serotype O:41 strains associated with Guillain-Barre syndrome. The MAbs reacted with ganglioside GM1 to different degrees, and these differences in fine specificities for GM1 were reflected in the different degrees of reactivity with each of the C. jejuni LPSs tested. Antibodies could also be discriminated by the varying patterns of inhibition by cholera toxin (a GM1 ligand) in LPS binding studies. These results indicate that there is a substantial heterogeneity among C. jejuni O:41 strains in their expression of GM1-like epitopes and among the fine specificities of different neuropathy-associated anti-GM1 antibodies.  (+info)

Polyradiculoneuropathy is a medical term that refers to a condition affecting multiple nerve roots and peripheral nerves. It's a type of neuropathy, which is damage or disease affecting the peripheral nerves, and it involves damage to the nerve roots as they exit the spinal cord.

The term "poly" means many, "radiculo" refers to the nerve root, and "neuropathy" indicates a disorder of the nerves. Therefore, polyradiculoneuropathy implies that multiple nerve roots and peripheral nerves are affected.

This condition can result from various causes, such as infections (like Guillain-Barre syndrome), autoimmune disorders (such as lupus or rheumatoid arthritis), diabetes, cancer, or exposure to toxins. Symptoms may include weakness, numbness, tingling, or pain in the limbs, which can progress and become severe over time. Proper diagnosis and management are crucial for improving outcomes and preventing further nerve damage.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare neurological disorder characterized by progressive and persistent inflammation of the peripheral nerves' myelin sheaths, leading to significant damage and impaired nerve function. Myelin is the fatty insulation that surrounds and protects nerve fibers, enabling efficient electrical conduction and communication between the brain, spinal cord, and muscles.

In CIDP, the immune system mistakenly attacks the myelin sheath, causing its gradual deterioration (demyelination) and subsequent impairment of nerve function. This results in symptoms such as progressive muscle weakness, numbness, tingling, or sensory loss affecting both sides of the body. The onset of CIDP can be either acute or insidious, with symptoms developing slowly over several months.

CIDP is typically classified into two categories based on the distribution of nerve involvement:

1. Distal acquired demyelinating symmetric (DADS) neuropathy: This form of CIDP affects the longest nerves first, leading to symmetrical sensory and motor disturbances in the feet and hands.
2. Asymmetric or multifocal acquired demyelinating sensory and motor neuropathy: In this form, the damage is more localized and asymmetrical, affecting various parts of the peripheral nervous system.

The diagnosis of CIDP relies on a combination of clinical presentation, electrodiagnostic studies (nerve conduction studies and electromyography), and supportive findings from cerebrospinal fluid analysis and nerve biopsy. Treatment usually involves immunosuppressive therapies to control the immune response and promote nerve recovery, such as corticosteroids, intravenous immunoglobulins, or plasma exchange. Early diagnosis and treatment can significantly improve outcomes and prevent long-term disability in patients with CIDP.

Compressed air is defined in a medical context as air that has been pressurized and forced into a smaller space or volume. It is often used in medical devices and treatments, such as in the case of aerosolized medications or in certain surgical procedures. Compressed air can also be used to power medical equipment, such as drills and saws.

It's important to note that the use of compressed air in medical settings must follow strict guidelines and regulations to ensure the safety and effectiveness of the treatment. For example, the air must be clean and free from contaminants, and the pressure must be carefully controlled to avoid causing harm to patients or healthcare providers.

Guillain-Barré syndrome (GBS) is a rare autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, tingling sensations, and sometimes paralysis. The peripheral nervous system includes the nerves that control our movements and transmit signals from our skin, muscles, and joints to our brain.

The onset of GBS usually occurs after a viral or bacterial infection, such as respiratory or gastrointestinal infections, or following surgery, vaccinations, or other immune system triggers. The exact cause of the immune response that leads to GBS is not fully understood.

GBS typically progresses rapidly over days or weeks, with symptoms reaching their peak within 2-4 weeks after onset. Most people with GBS experience muscle weakness that starts in the lower limbs and spreads upward to the upper body, arms, and face. In severe cases, the diaphragm and chest muscles may become weakened, leading to difficulty breathing and requiring mechanical ventilation.

The diagnosis of GBS is based on clinical symptoms, nerve conduction studies, and sometimes cerebrospinal fluid analysis. Treatment typically involves supportive care, such as pain management, physical therapy, and respiratory support if necessary. In addition, plasma exchange (plasmapheresis) or intravenous immunoglobulin (IVIG) may be used to reduce the severity of symptoms and speed up recovery.

While most people with GBS recover completely or with minimal residual symptoms, some may experience long-term disability or require ongoing medical care. The prognosis for GBS varies depending on the severity of the illness and the individual's age and overall health.

Polyradiculopathy is a medical term that refers to a condition affecting multiple nerve roots. It's a type of neurological disorder where there is damage or injury to the nerve roots, which are the beginning portions of nerves as they exit the spinal cord. This damage can result in various symptoms such as weakness, numbness, tingling, and pain in the affected areas of the body, depending on the specific nerves involved.

Polyradiculopathy can be caused by a variety of factors, including trauma, infection, inflammation, compression, or degenerative changes in the spine. Some common causes include spinal cord tumors, herniated discs, spinal stenosis, and autoimmune disorders such as Guillain-Barre syndrome.

Diagnosing polyradiculopathy typically involves a thorough neurological examination, imaging studies such as MRI or CT scans, and sometimes nerve conduction studies or electromyography (EMG) to assess the function of the affected nerves. Treatment for polyradiculopathy depends on the underlying cause but may include medications, physical therapy, surgery, or a combination of these approaches.

Plasma exchange, also known as plasmapheresis, is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies, clotting factors, or toxins, is then removed and replaced with fresh plasma or a plasma substitute. This process helps to remove the harmful substances from the blood and allows the body to replenish its own plasma with normal components. Plasma exchange is used in the treatment of various medical conditions including autoimmune diseases, poisonings, and certain types of kidney diseases.

Intravenous Immunoglobulins (IVIG) are a preparation of antibodies, specifically immunoglobulins, that are derived from the plasma of healthy donors. They are administered intravenously to provide passive immunity and help boost the immune system's response in individuals with weakened or compromised immune systems. IVIG can be used for various medical conditions such as primary immunodeficiency disorders, secondary immunodeficiencies, autoimmune diseases, and some infectious diseases. The administration of IVIG can help prevent infections, reduce the severity and frequency of infections, and manage the symptoms of certain autoimmune disorders. It is important to note that while IVIG provides temporary immunity, it does not replace a person's own immune system.

Demyelinating diseases are a group of disorders that are characterized by damage to the myelin sheath, which is the protective covering surrounding nerve fibers in the brain, optic nerves, and spinal cord. Myelin is essential for the rapid transmission of nerve impulses, and its damage results in disrupted communication between the brain and other parts of the body.

The most common demyelinating disease is multiple sclerosis (MS), where the immune system mistakenly attacks the myelin sheath. Other demyelinating diseases include:

1. Acute Disseminated Encephalomyelitis (ADEM): An autoimmune disorder that typically follows a viral infection or vaccination, causing widespread inflammation and demyelination in the brain and spinal cord.
2. Neuromyelitis Optica (NMO) or Devic's Disease: A rare autoimmune disorder that primarily affects the optic nerves and spinal cord, leading to severe vision loss and motor disability.
3. Transverse Myelitis: Inflammation of the spinal cord causing damage to both sides of one level (segment) of the spinal cord, resulting in various neurological symptoms such as muscle weakness, numbness, or pain, depending on which part of the spinal cord is affected.
4. Guillain-Barré Syndrome: An autoimmune disorder that causes rapid-onset muscle weakness, often beginning in the legs and spreading to the upper body, including the face and breathing muscles. It occurs when the immune system attacks the peripheral nerves' myelin sheath.
5. Central Pontine Myelinolysis (CPM): A rare neurological disorder caused by rapid shifts in sodium levels in the blood, leading to damage to the myelin sheath in a specific area of the brainstem called the pons.

These diseases can result in various symptoms, such as muscle weakness, numbness, vision loss, difficulty with balance and coordination, and cognitive impairment, depending on the location and extent of the demyelination. Treatment typically focuses on managing symptoms, modifying the immune system's response, and promoting nerve regeneration and remyelination when possible.

Neural conduction is the process by which electrical signals, known as action potentials, are transmitted along the axon of a neuron (nerve cell) to transmit information between different parts of the nervous system. This electrical impulse is generated by the movement of ions across the neuronal membrane, and it propagates down the length of the axon until it reaches the synapse, where it can then stimulate the release of neurotransmitters to communicate with other neurons or target cells. The speed of neural conduction can vary depending on factors such as the diameter of the axon, the presence of myelin sheaths (which act as insulation and allow for faster conduction), and the temperature of the environment.

... at the U.S. National Library of Medicine Medical Subject Headings (MeSH) v t e (Articles with short ... Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur together. An example is ... "Prolonged Remission of SLE-associated Polyradiculoneuropathy after a Single Course of Intravenous Immunoglobulin". Scandinavian ...
"Orphanet: Acute inflammatory demyelinating polyradiculoneuropathy". www.orpha.net. Retrieved 2016-08-26. "Chronic Inflammatory ... to pressure palsy Mononeuropathy Neuritis Neuromuscular disease Neuromuscular medicine Neuropathy Polyradiculoneuropathy Radial ...
Kissel JT (2003). "The treatment of chronic inflammatory demyelinating polyradiculoneuropathy". Seminars in Neurology. 23 (2): ... or polyradiculoneuropathy) is considered an autoimmune disorder destroying myelin, the protective covering of the nerves. ... Acute inflammatory demyelinating polyradiculoneuropathy Acute motor axonal neuropathy Acute motor and sensory axonal neuropathy ... or chronic inflammatory demyelinating polyradiculoneuropathy (because it involves the nerve roots). CIDP is closely related to ...
... they include acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute ataxia ... "Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews". The ...
... such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Friedreich's ataxia Ménière's disease Romberg's test ...
"A case of severe chronic progressive axonal polyradiculoneuropathy temporally associated with anti-CV2/CRMP5 antibodies". ...
Tracy, Jennifer A.; Dyck, P. James B. (1 June 2011). "Auto-immune polyradiculoneuropathy and a novel IgG biomarker in workers ... "An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a ...
Also anti-GM1 IgG has been identified in Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. ...
In 2006, Bruce was hospitalized due to the effects of chronic inflammatory demyelinating polyradiculoneuropathy, which he had ...
Polyneuropathies And Chronic Inflammatory Demyelinating Polyradiculoneuropathy In Multiple Sclerosis, Neurology April 6, 2015 ...
Other differential diagnoses to consider are Chronic Inflammatory Demyelinating Polyradiculoneuropathy, neoplastic lumbosacral ...
Hyperdynamic circulation Electric shock Drug withdrawal Porphyria Acute inflammatory demyelinating polyradiculoneuropathy ...
... polyradiculoneuropathy MeSH C20.111.258.750.400 - Guillain-Barré syndrome MeSH C20.111.258.750.400.500 - Miller Fisher syndrome ... polyradiculoneuropathy, chronic inflammatory demyelinating MeSH C20.111.258.850 - stiff-person syndrome MeSH C20.111.258.925 - ...
... polyradiculoneuropathy MeSH C10.668.829.800.750.300 - guillain-barre syndrome MeSH C10.668.829.800.750.300.500 - miller fisher ... polyradiculoneuropathy, chronic inflammatory demyelinating MeSH C10.114.875.175 - aids arteritis, central nervous system MeSH ... polyradiculoneuropathy, chronic inflammatory demyelinating MeSH C10.314.750.450 - guillain-barre syndrome MeSH C10.314.750.450. ... polyradiculoneuropathy, chronic inflammatory demyelinating MeSH C10.668.829.800.750.700 - polyradiculopathy MeSH C10.668. ...
Polyradiculoneuropathy at the U.S. National Library of Medicine Medical Subject Headings (MeSH) v t e (Articles with short ... Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur together. An example is ... "Prolonged Remission of SLE-associated Polyradiculoneuropathy after a Single Course of Intravenous Immunoglobulin". Scandinavian ...
Chronic Inflammatory Demyelinating Polyradiculoneuropathy * Skill Checkup: A 59-Year-Old Man With Cervical/Lumbar Dorsalgia, ... Acute Inflammatory Demyelinating Polyradiculoneuropathy. Updated: Jul 26, 2021 * Author: Emad R Noor, MBChB; Chief Editor: ... Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) and Transverse Myelitis: A Tale of West Nile Virus Infection. ... Osterman PO, Fagius J, Safwenberg J. Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with ...
Nerve ultrasound has been proven to be an accurate tool in diagnosing chronic inflammatory demyelinating polyradiculoneuropathy ... Nerve ultrasound has been proven to be an accurate tool in diagnosing chronic inflammatory demyelinating polyradiculoneuropathy ... Nerve ultrasound may help predicting response to immune treatment in chronic inflammatory demyelinating polyradiculoneuropathy ... Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 86:973- ...
Chronic inflammatory demyelinating polyradiculoneuropathy is a paralytic syndrome, causing considerable disability and even ... A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy Ann Neurol ... Chronic inflammatory demyelinating polyradiculoneuropathy is a paralytic syndrome, causing considerable disability and even ...
... for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled ... that intravenous immunoglobulin might reduce disability caused by chronic inflammatory demyelinating polyradiculoneuropathy ( ...
Chronic inflammatory demyelinating polyradiculoneuropathy is presumed to occur because of immunologic antibody-mediated ... Chronic Inflammatory Demyelinating Polyradiculoneuropathy * Fast Five Quiz: How Much Do You Know About Chronic Inflammatory ... Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Updated: Jun 13, 2018 * Author: Richard A Lewis, MD; Chief Editor: ... Chronic inflammatory demyelinating polyradiculoneuropathy may occur at any age, but it is more common in the fifth and sixth ...
Emsley, Hedley C. A. and Molloy, Jane (2002) Inflammatory demyelinating polyradiculoneuropathy associated with membranous ... examination and subsequent investigation confirmed a diagnosis of sub-acute inflammatory demyelinating polyradiculoneuropathy ( ...
Polyradiculoneuropathy in Addisons disease. Case report and review of literature. DILAWER H. ABBAS, R. E. SCHLAGENHAUFF, H. ...
"Polyradiculoneuropathy" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... This graph shows the total number of publications written about "Polyradiculoneuropathy" by people in this website by year, and ... Below are the most recent publications written about "Polyradiculoneuropathy" by people in Profiles. ... and POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING. Polyradiculoneuritis refers to inflammation of multiple ...
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), better known as Guillain-Barré syndrome (GBS), is a rapidly ... Acute inflammatory demyelinating polyradiculoneuropathy. Author Betty Soliven MD See Contributor Disclosures Editor Francesc ... Acute inflammatory demyelinating polyradiculoneuropathy occurs in all parts of the world and at all ages, with an incidence ... Acute inflammatory demyelinating polyradiculoneuropathy is thought to be a cell-mediated autoimmune disease of the peripheral ...
Acute Inflammatory Demyelinating Polyradiculoneuropathy. Updated: Mar 25, 2016 * Author: Tarakad S Ramachandran, MBBS, MBA, MPH ... Osterman PO, Fagius J, Safwenberg J. Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with ... encoded search term (Acute Inflammatory Demyelinating Polyradiculoneuropathy) and Acute Inflammatory Demyelinating ...
... treatment can help people with autoimmune diseases such as chronic inflammatory demyelinating polyradiculoneuropathy. ... Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a slowly developing autoimmune disorder in which the bodys ...
Chronic inflammatory demyelinating polyradiculoneuropathy is presumed to occur because of immunologic antibody-mediated ... Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Updated: Apr 03, 2014 * Author: Richard A Lewis, MD; Chief Editor: ... Chronic inflammatory demyelinating polyradiculoneuropathy may occur at any age, but it is more common in the fifth and sixth ... Chronic inflammatory demyelinating polyradiculoneuropathy: new views and guidelines. J Peripher Nerv Syst. 2005 Sep. 10(3):217- ...
Azathioprine, interferon beta-1a or methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy answers are ... Azathioprine, interferon beta-1a or methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy. Evidence-Based ... "Azathioprine, Interferon Beta-1a or Methotrexate for Chronic Inflammatory Demyelinating Polyradiculoneuropathy." Evidence-Based ... Azathioprine, interferon beta-1a or methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy Evidence ...
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Emily K Mathey et al., Journal of ... Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. Andoni ... Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. Marta Ruiz et al., Journal of Neurology, Neurosurgery ... Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy. Pietro Emiliano Doneddu et al ...
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Emily K Mathey et al., Journal of ... Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study. Andoni ... Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. Marta Ruiz et al., Journal of Neurology, Neurosurgery ... Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy. Pietro Emiliano Doneddu et al ...
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, ... Journal Review: Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach FREE ... Journal Review: Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach Course ...
Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management * 2001/viewarticle/defining- ... Fast Five Quiz: How Much Do You Know About Chronic Inflammatory Demyelinating Polyradiculoneuropathy? ...
Chronic inflammatory demyelinating polyradiculoneuropathy; Polyneuropathy - chronic inflammatory; CIDP; Chronic inflammatory ...
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP by Chronic Inflammatory Demyelinating Polyradiculoneuropathy, ... Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP by MohamadAlhes. Chronic Inflammatory Demyelinating ...
The heterogeneous group of muscle diseases known as periodic paralyses (PP) is characterized by episodes of flaccid muscle weakness occurring at irregular intervals. Most of the conditions are hereditary and are more episodic than periodic.
Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on ... Objectives: To determine the prevalence of different comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy ... Objectives: To determine the prevalence of different comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy ...
MRI may provide treatment outcome measures in neuromuscular conditions. The authors assessed MRI magnetisation transfer ratios (MTRs) in lower-limb musculature as markers of pathology in peripheral neuropathies and compared the findings with associated clinical data. Ten patients with Charcot-Marie-Tooth disease type 1A (CMT1A) and nine patients with chronic inflammatory demyelinating polyneuropathy (CIDP) were compared with 10 healthy subjects. The MTR in the calf muscles was significantly lower than controls in the two patient groups (both p,0.001). The median MTRs (IQR) were 50.5(1.6) percentage units (p.u.) (control), 41.5(10.6) p.u. (CMT1A) and 39.3(8.7) p.u. (CIDP). Moreover, anterior lower leg MTR correlated strongly with strength of ankle dorsiflexion, measured with the Medical Research Council scale, in CIDP (ρ=0.88, p,0.001) and also in CMT1A (ρ=0.50, p,0.05), where MTR also showed an association with disease duration (ρ=−0.86, p,0.001). Short tau inversion recovery MRI of the ...
Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136- ... Randomized controlled trial of IVIG in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56( ... Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2002:CD002062. [ ... Intra-venous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol. ...
Severe sensorimotor polyradiculoneuropathy after ingestion of ethylene glycol. J Neurol Neurosurg Psychiatry 63(2):261. ...
Categories: Polyradiculoneuropathy Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
Neuroprotection in chronic inflammatory demyelinating polyradiculoneuropathy. *Neuroprotection in Charcot-Marie-Tooth disease ...
Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-9. ... Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2:1296-9. ... acute inflammatory demyelinating polyradiculoneuropathy (AIDP), which is sensory and motor and displays demyelinating changes ...
Synonyms and keywords: Acute inflammatory demyelinating polyradiculoneuropathy Overview. Historical Perspective. Classification ...
  • Nerve ultrasound has been proven to be an accurate tool in diagnosing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). (springer.com)
  • Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH et al (2015) Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. (springer.com)
  • Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. (springer.com)
  • Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA (2019) Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. (springer.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy is a paralytic syndrome, causing considerable disability and even death. (nih.gov)
  • Short-term studies suggest that intravenous immunoglobulin might reduce disability caused by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not been shown. (nih.gov)
  • The term chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been used to identify patients with a chronically progressive or relapsing symmetric sensorimotor disorder with cytoalbuminologic dissociation and interstitial and perivascular endoneurial infiltration by lymphocytes and macrophages. (medscape.com)
  • It can be considered the chronic equivalent of acute inflammatory demyelinating polyradiculoneuropathy, the most common form of Guillain-Barré syndrome. (medscape.com)
  • Electron micrograph of the peripheral nerve of a patient with chronic inflammatory demyelinating polyradiculoneuropathy. (medscape.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy is presumed to occur because of immunologic antibody-mediated reaction along with interstitial and perivascular infiltration of the endoneurium with inflammatory T cells and macrophages. (medscape.com)
  • Clinical examination and subsequent investigation confirmed a diagnosis of sub-acute inflammatory demyelinating polyradiculoneuropathy (sub-acute IDP). (lancs.ac.uk)
  • Acute inflammatory demyelinating polyradiculoneuropathy is the most frequent pattern of Guillain-Barré syndrome encountered in North America and Europe. (medlink.com)
  • In this review, the author explains the clinical features, criteria for diagnosis, advances in the pathogenesis, and treatment of acute inflammatory demyelinating polyradiculoneuropathy. (medlink.com)
  • Acute inflammatory demyelinating polyradiculoneuropathy is an inflammatory disease of the peripheral nervous system characterized by lymphocytic and macrophagic infiltration with destruction of myelin. (medlink.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a slowly developing autoimmune disorder in which the body's immune system attacks the myelin that insulates and protects your body's nerves. (innovitalife.com)
  • Investigations confirmed a demyelinating neuropathy, with nerve conduction studies fulfilling electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). (bmj.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patientsʼ ability to walk and perform activities of daily living independently. (aanem.org)
  • Objectives: To determine the prevalence of different comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and their impact on outcome, treatment choice and response. (hunimed.eu)
  • Autoimmune neuropathies encompass acute forms such as Guillain-Barre syndrome (GBS) and its variants, as well as chronic forms including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy, and polyneuropathies associated with immunoglobulin M (IgM) monoclonal gammopathy and paraneoplastic neuropathies. (nursingcenter.com)
  • The diagnosis of GBS is clinical but may be aided by electrophysiology which is also important to characterise the two main electrophysiological subtypes: acute inflammatory demyelinating polyradiculoneuropathy (AIDP), which is sensory and motor and displays demyelinating changes on nerve conduction studies, and acute motor axonal neuropathy (AMAN), which is primarily axonal and thought to be purely motor. (bmj.com)
  • Fast Five Quiz: How Much Do You Know About Chronic Inflammatory Demyelinating Polyradiculoneuropathy? (medscape.com)
  • The most common subtypes are acute inflammatory demyelinating polyradiculoneuropathy and acute motor axonal neuropathy. (standardofcare.com)
  • Approximately 90% of people with GBS in North America and Europe have acute inflammatory demyelinating polyradiculoneuropathy. (standardofcare.com)
  • Guillain-Barre is a nice easy to remember name for acute inflammatory demyelinating polyradiculoneuropathy. (bodybuilding.com)
  • Investigators identified 3 records comparing IVIG and TPE efficacy in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). (pharmacytimes.com)
  • Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is the most common subtype. (alliedacademies.org)
  • Immune-mediated polyradiculoneuropathies are divided into Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). (unicamp.br)
  • In children subacute inflammatory demyelinating polyradiculoneuropathy is included in CIDP. (unicamp.br)
  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nervous system disease associated with polyautoimmunity. (turkishjournalpediatrics.org)
  • Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur together. (wikipedia.org)
  • Immune polyradiculoneuropathies are not exclusively demyelinating, and axonal forms also responding favourably to immunotherapy occur. (unicamp.br)
  • Follow-up findings in confirmed cases of what investigators call immune polyradiculoneuropathy or progressive inflammatory neuropathy were released February 24 but will be formally presented at the upcoming American Academy of Neurology 61st Annual Meeting, in Seattle, which will take place April 25 to May 2. (medscape.com)
  • 1997. Severe sensorimotor polyradiculoneuropathy after ingestion of ethylene glycol. (cdc.gov)
  • Botulism is frequently misdiagnosed, most often as a polyradiculoneuropathy (Guillain-Barré or Miller-Fisher syndrome), myasthenia gravis, or other diseases of the central nervous system. (cdc.gov)
  • Guillain-Barre syndrome is a post infectious ascending, usually demyelinationg polyradiculoneuropathy. (banglajol.info)
  • This graph shows the total number of publications written about "Polyradiculoneuropathy" by people in this website by year, and whether "Polyradiculoneuropathy" was a major or minor topic of these publications. (childrensmercy.org)
  • Below are the most recent publications written about "Polyradiculoneuropathy" by people in Profiles. (childrensmercy.org)
  • Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. (medscape.com)
  • Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. (medscape.com)
  • Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. (medscape.com)
  • Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. (medscape.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy: new views and guidelines. (medscape.com)
  • Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. (medscape.com)
  • A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. (medscape.com)
  • European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. (medscape.com)
  • As reliable biomarkers of disease activity are lacking, monitoring of therapeutic response in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) remains a challenge. (springer.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy can be caused by multiple diseases, from infectious as well as immunology diseases. (nih.gov)
  • This activity reviews the evaluation, diagnosis, and treatment of neuropathy, demyelinating polyradiculoneuropathy, chronic, and inflammatory, and highlights the role of the interprofessional team in evaluating and treating patients with this condition. (nih.gov)
  • Describe the pathophysiology, of chronic inflammatory demyelinating polyradiculoneuropathy. (nih.gov)
  • Review the risk factors for developing chronic inflammatory demyelinating polyradiculoneuropathy. (nih.gov)
  • Summarize the management options available for chronic inflammatory demyelinating polyradiculoneuropathy. (nih.gov)
  • The term chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been used to identify patients with a chronically progressive or relapsing symmetric sensorimotor disorder with cytoalbuminologic dissociation and interstitial and perivascular endoneurial infiltration by lymphocytes and macrophages. (medscape.com)
  • It can be considered the chronic equivalent of acute inflammatory demyelinating polyradiculoneuropathy, the most common form of Guillain-Barré syndrome. (medscape.com)
  • Electron micrograph of the peripheral nerve of a patient with chronic inflammatory demyelinating polyradiculoneuropathy. (medscape.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy is presumed to occur because of immunologic antibody-mediated reaction along with interstitial and perivascular infiltration of the endoneurium with inflammatory T cells and macrophages. (medscape.com)
  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disorder of the peripheral nerves with clinical and immunological heterogeneity. (nih.gov)
  • Dataset related to article "Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria? (openaire.eu)
  • Abstract Background and purpose: The aim was to identify the clinical and diagnostic investigations that may help to support a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients not fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria. (openaire.eu)
  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common chronic immune-mediated inflammatory polyneuropathy. (medscape.com)
  • 3. [The clinical analysis of diabetic patients with chronic inflammatory demyelinating polyradiculoneuropathy]. (nih.gov)
  • 11. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus. (nih.gov)
  • The most common type of Guillain-Barré syndrome is acute inflammatory demyelinating polyradiculoneuropathy (AIDP). (nih.gov)
  • My name is James and I have Chronic Inflammatory Demyelinating Polyradiculoneuropathy. (caninepartners.org.uk)
  • The disorder is sometimes called chronic relapsing polyneuropathy (CRP) or chronic inflammatory demyelinating polyradiculoneuropathy (because it involves the nerve roots). (checkorphan.org)
  • Octagam® 10% also is indicated for primary immunodeficiency, secondary immunodeficiencies and Guillain Barré syndrome in the EU and Canada, and adult dermatomyositis in the EU and U.S., and for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), and Kawasaki disease in the EU. (octapharma.com)
  • Autoimmune disorders like Sjögren's Syndrome, lupus, rheumatoid arthritis, fibromyalgia, Guillain-Barré Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy cause inflammation that can damage nerves and lead to neuropathy. (hartfordhealthcare.org)
  • Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia. (viamedica.pl)
  • Ddx: may be confused w/ acute inflammatory demyelinating polyradiculoneuropathy (AIDP) or GB. (hopkinsguides.com)
  • 3. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews . (neuropathycommons.org)
  • Chronic inflammatory demyelinating polyradiculoneuropathies (CIDP) is a type of acquired immune-mediated disorder that affects the peripheral nervous system. (nih.gov)
  • No article was found for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating and SH2D2A[original query] . (cdc.gov)
  • 1997. Severe sensorimotor polyradiculoneuropathy after ingestion of ethylene glycol. (cdc.gov)
  • Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur together. (wikipedia.org)
  • All patients developed polyradiculoneuropathy, which was usually sensory predominant and painful. (elsevierpure.com)